Microfluidic Systems for Cancer Diagnosis and Applications

Akgönüllü, Semra; Bakhshpour, Monireh; Pişkin, A. Kevser; Deni̇zli̇, Adil

doi:10.3390/mi12111349

Cited by 31 publications

(18 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microfluidic platforms are micromanufactured devices with interconnected chambers, membranes, and grooves that share low volumes of fluids ( Figure 6 ), which have been widely applied for in vitro modeling such as organ-on-a-chip models ( 49 , 90 – 95 ) and point-of-care systems ( 96 ). In cancer research, microfluidic platforms are mostly fabricated using lithography and surface micromatching techniques with polydimethylsiloxane, silicon, glass, polycarbonate, and polymethylmethacrylate as main materials ( 49 , 91 – 93 , 97 – 99 ). Flow mechanisms can be implemented through a passive or an active approach within the microfluidic device.…”

Section: Microfluidic Platformsmentioning

confidence: 99%

In vitro models for head and neck cancer: Current status and future perspective

et al. 2022

View full text Add to dashboard Cite

The 5-year overall survival rate remains approximately 50% for head and neck (H&N) cancer patients, even though new cancer drugs have been approved for clinical use since 2016. Cancer drug studies are now moving toward the use of three-dimensional culture models for better emulating the unique tumor microenvironment (TME) and better predicting in vivo response to cancer treatments. Distinctive TME features, such as tumor geometry, heterogenous cellularity, and hypoxic cues, notably affect tissue aggressiveness and drug resistance. However, these features have not been fully incorporated into in vitro H&N cancer models. This review paper aims to provide a scholarly assessment of the designs, contributions, and limitations of in vitro models in H&N cancer drug research. We first review the TME features of H&N cancer that are most relevant to in vitro drug evaluation. We then evaluate a selection of advanced culture models, namely, spheroids, organotypic models, and microfluidic chips, in their applications for H&N cancer drug research. Lastly, we propose future opportunities of in vitro H&N cancer research in the prospects of high-throughput drug screening and patient-specific drug evaluation.

show abstract

Section: Microfluidic Platformsmentioning

confidence: 99%

In vitro models for head and neck cancer: Current status and future perspective

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although liquid biopsy is less frequently used than other techniques, it does offer many promising benefits, including reduced cost, greater convenience, and greater sensitivity [125]. The need for low-abundant blood and serum cancer diagnosis with microfluidic tools and the progress in developing integrated microfluidic platforms to meet this need has recently been summarized [126].…”

Section: Detection Techniques Of Breast Cancermentioning

confidence: 99%

Application of Microfluidic Systems for Breast Cancer Research

et al. 2022

View full text Add to dashboard Cite

Cancer is a disease in which cells in the body grow out of control; breast cancer is the most common cancer in women in the United States. Due to early screening and advancements in therapeutic interventions, deaths from breast cancer have declined over time, although breast cancer remains the second leading cause of cancer death among women. Most deaths are due to metastasis, as cancer cells from the primary tumor in the breast form secondary tumors in remote sites in distant organs. Over many years, the basic biological mechanisms of breast cancer initiation and progression, as well as the subsequent metastatic cascade, have been studied using cell cultures and animal models. These models, although extremely useful for delineating cellular mechanisms, are poor predictors of physiological responses, primarily due to lack of proper microenvironments. In the last decade, microfluidics has emerged as a technology that could lead to a paradigm shift in breast cancer research. With the introduction of the organ-on-a-chip concept, microfluidic-based systems have been developed to reconstitute the dominant functions of several organs. These systems enable the construction of 3D cellular co-cultures mimicking in vivo tissue-level microenvironments, including that of breast cancer. Several reviews have been presented focusing on breast cancer formation, growth and metastasis, including invasion, intravasation, and extravasation. In this review, realizing that breast cancer can recur decades following post-treatment disease-free survival, we expand the discussion to account for microfluidic applications in the important areas of breast cancer detection, dormancy, and therapeutic development. It appears that, in the future, the role of microfluidics will only increase in the effort to eradicate breast cancer.

show abstract

“…The availability of efficient, cheaper, and simple methods and/or devices for bioanalysis is therefore of great interest for medicine, biopharma and agriculture for food quality determination applications, especially if portable, fast, easy, using pL and nL of protein solution and with better detection limits respect to the current ones even in microfluidics implemented platforms [ 26 , 27 , 28 , 29 , 30 , 31 , 32 ].…”

Section: Introductionmentioning

confidence: 99%

Opto-Microfluidic Integration of the Bradford Protein Assay in Lithium Niobate Lab-on-a-Chip

Zanini¹,

Zaltron²,

Turato³

et al. 2022

Sensors

View full text Add to dashboard Cite

This paper deals with the quantification of proteins by implementing the Bradford protein assay method in a portable opto-microfluidic platform for protein concentrations lower than 1.4 mg/mL. Absorbance is measured by way of optical waveguides integrated to a cross-junction microfluidic circuit on a single lithium niobate substrate. A new protocol is proposed to perform the protein quantification based on the high correlation of the light absorbance at 595 nm, as commonly used in the Bradford method, with the one achieved at 633 nm with a cheap commercially available diode laser. This protocol demonstrates the possibility to quantify proteins by using nL volumes, 1000 times less than the standard technique such as paper-analytical devices. Moreover, it shows a limit of quantification of at least 0.12 mg/mL, which is four times lower than the last literature, as well as a better accuracy (98%). The protein quantification is obtained either by using one single microfluidic droplet as well by performing statistical analysis over ensembles of several thousands of droplets in less than 1 min. The proposed methodology presents the further advantage that the protein solutions can be reused for other investigations and the same pertains to the opto-microfluidic platform.

show abstract

Microfluidic Systems for Cancer Diagnosis and Applications

Cited by 31 publications

References 98 publications

In vitro models for head and neck cancer: Current status and future perspective

In vitro models for head and neck cancer: Current status and future perspective

Application of Microfluidic Systems for Breast Cancer Research

Opto-Microfluidic Integration of the Bradford Protein Assay in Lithium Niobate Lab-on-a-Chip

Contact Info

Product

Resources

About